554 related articles for article (PubMed ID: 33926386)
1. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
[TBL] [Abstract][Full Text] [Related]
2. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
3. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
4. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
6. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
Imazu M; Nakano A; Ito S; Hamasaki T; Kitakaze M;
Cardiovasc Drugs Ther; 2019 Jun; 33(3):363-370. PubMed ID: 30850916
[TBL] [Abstract][Full Text] [Related]
7. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
Matsutani D; Sakamoto M; Kayama Y; Takeda N; Horiuchi R; Utsunomiya K
Cardiovasc Diabetol; 2018 May; 17(1):73. PubMed ID: 29788955
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
Lan NSR; Yeap BB; Fegan PG; Green G; Rankin JM; Dwivedi G
Int J Cardiovasc Imaging; 2021 Feb; 37(2):517-527. PubMed ID: 32959096
[TBL] [Abstract][Full Text] [Related]
9. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
[TBL] [Abstract][Full Text] [Related]
10. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
11. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
Natali A; Nesti L; Fabiani I; Calogero E; Di Bello V
Cardiovasc Diabetol; 2017 Oct; 16(1):130. PubMed ID: 29025406
[TBL] [Abstract][Full Text] [Related]
12. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
[TBL] [Abstract][Full Text] [Related]
13. Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus.
Yokota S; Tanaka H; Mochizuki Y; Soga F; Yamashita K; Tanaka Y; Shono A; Suzuki M; Sumimoto K; Mukai J; Suto M; Takada H; Matsumoto K; Hirota Y; Ogawa W; Hirata KI
Cardiovasc Diabetol; 2019 Dec; 18(1):166. PubMed ID: 31805945
[TBL] [Abstract][Full Text] [Related]
14. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
15. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
[TBL] [Abstract][Full Text] [Related]
16. Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus.
Kozakova M; Morizzo C; Fraser AG; Palombo C
Cardiovasc Diabetol; 2017 Jun; 16(1):78. PubMed ID: 28623932
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure.
Wang DD; Naumova AV; Isquith D; Sapp J; Huynh KA; Tucker I; Balu N; Voronyuk A; Chu B; Ordovas K; Maynard C; Tian R; Zhao XQ; Kim F
Cardiovasc Diabetol; 2024 Jun; 23(1):197. PubMed ID: 38849829
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
[TBL] [Abstract][Full Text] [Related]
19. Association of left ventricular longitudinal myocardial function with subclinical right ventricular dysfunction in type 2 diabetes mellitus.
Todo S; Tanaka H; Yamauchi Y; Yokota S; Mochizuki Y; Shiraki H; Yamashita K; Shono A; Suzuki M; Sumimoto K; Tanaka Y; Hirota Y; Ogawa W; Hirata KI
Cardiovasc Diabetol; 2021 Oct; 20(1):212. PubMed ID: 34688280
[TBL] [Abstract][Full Text] [Related]
20. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
